“Bangladesh has shown low HIV prevalence rates so far but may be silently moving towards an epidemic, say experts pointing to underreporting and poor monitoring for the virus in the general population,” Inter Press Service reports. “Professionals and volunteers working in the HIV/AIDS field say there is no room for complacency and that Bangladesh may well be on the brink of an epidemic, going by continuing high levels of STDs alone,” the news service writes.
“Chagas disease, a parasitic infection spread to humans by insects, is not the new HIV/AIDS of the Americas, according to infectious disease experts who called the comparison,” made in an editorial published in PLoS Neglected Tropical Diseases last week, “‘unrealistic’ and ‘unfortunate,'” ABC News’ “Medical Unit” blog reports. “Rick Tarleton, president of the Chagas Disease Foundation, said the diseases have little in common beyond disproportionately affecting poor people,” the blog notes (Moisse, 6/1).
Ghana “will contribute about $1 million towards the prevention and control of endemic neglected tropical diseases (NTDs) in order to protect the gains made by the country in Guinea worm eradication and the elimination of trachoma,” the country’s health minister announced on Monday at the opening of a Regional Stakeholders’ Consultative Meeting on NTDs, PANA/AfriqueJet reports. Health Minister Albin Bagbin “also called on African countries to support interventions to address NTDs and improve coordination among all stakeholders in implementing NTD programs,” the news agency writes.
AllAfrica.com/Guardian examine efforts to prevent and treat cervical cancer among women in Kenya, where an estimated 3,400 women die of the disease each year and only five percent receive screening. “Kenya’s national reproductive health strategic plan has addressed cervical cancer largely through the roll-out of a low-cost screening tool known as VIA (visual inspection of the cervix using ascetic acid),” but experts agree that more widespread use of cervical cancer vaccines and public education campaigns about the disease would be more effective at preventing and catching cases earlier, the news service reports. “Once the public owns this problem and pushes for it, … then the government would be forced to implement [a vaccine] strategy in full,” Lucy Muchiri, a pathologist specializing in cervical cancer at Kenyatta National Hospital and the University of Nairobi, said, the news service notes (Njoroge, 6/12).
“[C]ooperation is essential to combat diseases that cross national borders,” Ramanan Laxminarayan, director of the Center for Disease Dynamics, Economics and Policy and a research scholar and lecturer at Princeton University, and Bryan Grenfell and Petra Klepac of Princeton University write in a SciDev.Net opinion piece. “This is not restricted to regional control — long-term, coordinated efforts that give neighboring countries an incentive to immunize or put in place other intervention measures can also lead to global elimination of a disease,” they write, discussing optimal vaccination strategies and disease control challenges.
In a study published on Wednesday in the Lancet, researchers from the Centers for Disease Control and Prevention found that “[a]mong 1,278 patients who were resistant to two or more first-line tuberculosis drugs in Estonia, Latvia, Peru, Philippines, Russia, South Africa, South Korea and Thailand, 43.7 percent showed resistance to at least one second-line drug,” which “suggest[s] the deadly disease may become ‘virtually untreatable,'” according to the study, Bloomberg Businessweek reports (Kitamura/Narayan, 8/29). “In about a fifth of cases, they found resistance to at least one second-line injectable [versus oral] drug,” according to Reuters, which states “[t]his ranged from two percent in the Philippines to 47 percent in Latvia.” Overall, 6.7 percent of patients had extensively drug-resistant TB (XDR-TB), meaning patients are resistant to the first-line drugs isoniazid and rifampicin as well as drugs in the fluoroquinolone antibiotic class and a second-line injectable antibiotic, Reuters adds, noting “[r]ates in South Korea, at 15.2 percent, and Russia at 11.3 percent, were more than twice the WHO’s global estimate of 5.4 percent at that time” (Kelland, 8/30).
As the BRIC countries — Brazil, Russia, India, and China — invest more in innovations in health technologies and other areas, “many are looking to these countries to correct the global health research and development (R&D) imbalance that leaves the poor without needed products such as an improved tuberculosis (TB) vaccine or tests to help diagnose patients in remote rural settings,” David de Ferranti, president of Results for Development Institute (R4D), writes in the Huffington Post Blog. Writing that “India, which has already played such an important role in manufacturing affordable antiretroviral drugs, vaccines, and other essential health commodities for developing countries,” de Ferranti asks whether India “is … ready to play a leading role in health R&D?”
In an article on the U.S. Department of Defense webpage, the American Forces Press Service reports on the first U.S. National Strategy for Biosurveillance, issued by the White House “to quickly detect a range of global health and security hazards.” According to the article, “the Defense Department has a running start in implementing the new plan, a senior defense official said,” and “many of the activities described in the strategy are ongoing at DOD.” “So much of what we’re doing is integrating the efforts and working hard on the overlap between global security and global health, in what [President Barack Obama] refers to as global health security,” said Andrew Weber, assistant secretary of defense for nuclear, chemical and biological defense programs, the news service writes (Pellerin, 8/22).
“Researchers have identified a mysterious new disease that has left scores of people in Asia and some in the United States with AIDS-like symptoms even though they are not infected with HIV,” the Associated Press reports. “This is another kind of acquired immune deficiency that is not inherited and occurs in adults, but doesn’t spread the way AIDS does through a virus, said Dr. Sarah Browne, a scientist at the National Institute of Allergy and Infectious Diseases,” who “helped lead the study with researchers in Thailand and Taiwan where most of the cases have been found since 2004,” according to the news service. “Researchers are calling this new disease an ‘adult-onset’ immunodeficiency syndrome because it develops later in life and they don’t know why or how,” AP writes, adding, “The fact that nearly all the patients so far have been Asian or Asian-born people living elsewhere suggests that genetic factors and something in the environment such as an infection may trigger the disease, researchers conclude” (Marchione, 8/22).
Diagnostics company Cepheid on Monday signed deals with PEPFAR, USAID, UNITAID, and the Bill & Melinda Gates Foundation to immediately reduce the price of its Xpert MTB/RIF test kit for its GeneXpert tuberculosis (TB) diagnostic system in 145 countries, Reuters reports. “The agreements will see the test sold for $9.98, down from its current price of $16.86 per test,” the news service writes, adding, “Cepheid said the Bill & Melinda Gates Foundation will make an initial payment of $3.5 million to make the test immediately available at the lower price” (Ail, 8/6).